arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Unicycive Therapeutics, Inc.

UNCY
$3.46 ▼ -0.28 (-7.49%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Unicycive Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $93.1M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -15.0% ↗
FCF / Share $-0.28 ↘
Trailing P/E —
Price / Book 1.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-12.82M
— 0.0% —
FCF / Share Free cash flow per share
$-0.28
↓ -8.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality ↑
72

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters